NASDAQ
15.01USD
-0.79 (-5.00%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
588.7M
P/E
—
EPS
—
Beta
0.15
52W range
5.8125-17.352
Day range
14.96–15.77
Open
15.77
Prev close
15.80
Volume
82.4K
Avg volume
159.5K
Dividend
0.00
IPO
2019-04-17
https://seekingalpha.com/article/4931398-brainsway-stock-capital-light-interventional-psychiatry-ecosystem · 8/6/2026+0.90
https://www.zacks.com/commentary/2952072/new-strong-buy-stocks-for-july-14th?cid=CS-STOCKNEWSAPI-FT-zacks_1_rank_additions-2952072 · 7/14/2026+1.00
https://www.gurufocus.com/news/8810984/brainsway-ltd-bway-stock-up-34-but-gf-value-says-overvalued-gf-score-68100 · 4/22/2026+0.60
https://www.zacks.com/stock/news/2893927/why-brainsway-bway-might-be-well-poised-for-a-surge · 4/2/2026+1.00
https://www.benzinga.com/trading-ideas/long-ideas/26/03/51060845/top-3-health-care-stocks-that-could-lead-to-your-biggest-gains-in-q1-2 · 3/5/2026+0.60
https://www.globenewswire.com/news-release/2025/11/17/3189024/17676/en/BrainsWay-Launches-First-Clinical-Trial-of-Deep-TMS-360-System-for-Alcohol-Use-Disorder.html · 11/17/2025+0.60
https://www.zacks.com/stock/news/2778819/brainsway-ltd-sponsored-adr-bway-hits-fresh-high-is-there-still-room-to-run?cid=CS-STOCKNEWSAPI-FT-52_week_high-2778819 · 10/28/2025+0.80
https://www.globenewswire.com/news-release/2025/08/13/3132471/17676/en/BrainsWay-Reports-Second-Quarter-2025-Financial-Results-and-Operational-Highlights.html · 8/13/2025+0.90
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
